Filing Details

Accession Number:
0001209191-18-055685
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-19 16:32:49
Reporting Period:
2018-10-17
Accepted Time:
2018-10-19 16:32:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346830 Cara Therapeutics Inc. CARA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1664708 Mani Mohindru C/O Cara Therapeutics, Inc.
4 Stamford Plaza,107 Elm Street, 9Th Fl
Stamford CT 06902
Cfo & Chief Strategy Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-17 16,042 $14.06 16,042 No 4 M Direct
Common Stock Disposition 2018-10-17 16,042 $20.19 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-10-17 16,042 $0.00 16,042 $14.06
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
368,958 2027-08-15 No 4 M Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 - $20.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  3. One-fourth (1/4th) of the shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date.